SYMPHOGEN - Sympress II Production System Enables Antibody Manufacturing - Gilde Healthcare

SYMPHOGEN – Sympress II Production System Enables Antibody Manufacturing

April 26, 2010

Company demonstrates ability to manufacture for large therapeutic markets

COPENHAGEN, Denmark and PRINCETON, New Jersey – Symphogen A/S today announced the publication of data in the March 20, 2010 online edition of Molecular Biotechnology by Nielsen LS et al. [epub ahead of print] demonstrating the ability of its Sympress II technology to enable cost-effective production of recombinant polyclonal antibodies (rpAb) and antibody mixtures with batch-to-batch consistency that the Company believes could supply drug product for large indications such as cancer and infectious disease. The Sympress II results demonstrated single-batch production of compositions with as many as six antibodies with a controlled and appropriate distribution in the final product.

“These published results indicate that Symphogen is now the only company that has overcome previous production limitations for rpAbs and so has enabled the cost effective single batch production at cost of goods sold that compares favorably with monoclonal antibody manufacturing,”

stated Kirsten Drejer, M.Sc. and Ph.D., Chief Executive Officer of Symphogen.

“We very much look forward to deploying Sympress II in the manufacturing of the rpAbs in our pipeline as they proceed through preclinical and clinical trials.”

Symphogen employs target-speci?c rpAbs, which represent a new generation of antibodies that mimic the diversity, speci?city, and binding capability of the natural human immune system. Such rpAb preparations contain several specific antibodies, all of which in the Sympress II production system can be produced in the same culture vessel. The Sympress II technology takes advantage of industry standard fed batch manufacturing processes for controlled production of recombinant polyclonal compositions.
 
Sympress II builds upon Symphogen’s earlier Sympress I technology, which has demonstrated highly reproducible, stable single batch production, but has a lower yield due to site-specific integration of a single antibody gene per cell making it best tailored for drug production to niche indications. The Sympress II production system utilizes a combination of random gene integration together with a new high producer Chinese Hamster Ovary (CHO) cell line, Enhanced Chinese Hamster Ovary (ECHO), as well as other improvements, which generated the same stability and reproducibility as the Sympress I technology and on top of that resulted in more than 10-fold higher yields. Furthermore, the generation of rpAb compositions with completely different target specificities was demonstrated suggesting that the Sympress II production system is generally applicable to rpAb manufacturing for large indications.
 
About Symphogen
Symphogen is developing superior antibody therapeutics (monoclonal, monoclonal mixtures and polyclonal) to help people with serious diseases and significant unmet medical needs. With its proprietary, unique Symplex? discovery and Sympress? manufacturing platforms, the company captures the diversity and specificity of the natural immune response in rationally designed recombinant antibody compositions. Symphogen is maturing a diversified pipeline of internal and partnered products across multiple indications including cancer, autoimmune and infectious disease. Symphogen is a private biopharmaceutical company headquartered in Copenhagen, Denmark, with a US subsidiary in Princeton, New Jersey.
 
Contacts:
Kirsten Drejer, Chief Executive Officer
Symphogen A/S
+45 6118 7494 or +45 2210 9959
 
Adriann Sax, Chief Business Officer
Symphogen, Inc.
+1 908 794 1085 
 
Kathryn Morris (media)
+1 845 635 9828

Gilde Healthcare raises €600 million to invest in healthcare innovation

A balanced mix of international investors commits €600 million to Gilde Healthcare Venture&Growth VI, a transatlantic investment fund Gilde Healthcare invests in fast growing companies that enable better care at lower cost, supported by its...
April 19, 2023

Gilde Healthcare portfolio company Moximed obtains FDA Market Authorization of the MISHA™ Knee System for People Suffering from Knee Osteoarthritis

Implantable shock absorber (ISA) relieves pain and improves function in people ineligible for, or unwilling to undergo, joint replacement MISHA Knee System is implanted during an outpatient procedure; it's the first and only device of...
April 13, 2023

Gilde Healthcare company Adcendo announces extension of series A financing to EUR 82M to develop its first-in-class ADC pipeline

Gilde Healthcare portfolio company Adcendo Aps (‘Adcendo’), focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of cancers with a high unmet medical need, today announces the successful completion of a Series...
April 4, 2023